WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) — EyePoint, Inc. (Nasdaq: EYPT), an organization dedicated to growing and commercializing therapeutics to assist enhance the lives of sufferers with critical retinal ailments, right this moment introduced that the Firm granted non-statutory inventory choices to new workers as inducement awards exterior the Firm’s 2023 Lengthy-Time period Incentive Plan in accordance with NASDAQ Itemizing Rule 5635(c)(4).
The Firm granted inventory choices to buy as much as an mixture of 20,000 shares of EyePoint widespread inventory to 6 new workers. The inventory choices had been granted on March 13, 2026. The grants had been accepted by the Compensation Committee and made as an inducement materials to every worker coming into into employment with EyePoint in accordance with NASDAQ Itemizing Rule 5635(c)(4). The choice awards have an train worth of $13.20 per share, the closing worth of EyePoint’s widespread inventory on March 13, 2026. The choices have a ten-year time period and vest over 4 years, with 25% of the unique variety of shares vesting on the primary anniversary of the relevant worker’s date of grant and the rest vesting in equal month-to-month installments over the next three years. Vesting of the choices is topic to the worker’s continued service with EyePoint by the relevant vesting dates.
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical firm dedicated to growing and commercializing progressive therapeutics to enhance the lives of sufferers with critical retinal ailments. The Firm’s lead product candidate, DURAVYU™, is an progressive investigational sustained supply remedy for critical retinal ailments combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ expertise. Supported by strong security and efficacy information throughout a number of scientific trials and indications, DURAVYU is at present being evaluated in Part 3 pivotal trials for moist age-related macular degeneration (moist AMD) and diabetic macular edema (DME). Topline information is anticipated for moist AMD starting in mid-2026.
The Firm is dedicated to partnering with the retina neighborhood to enhance affected person lives whereas creating long-term worth, with 4 accepted medication over three a long time and tens of 1000’s of eyes handled with EyePoint innovation.
More Read
EyePoint is headquartered in Watertown, Massachusetts, with a business manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint solely by Equinox Sciences, a Betta Prescribed drugs affiliate, for the localized remedy of all ophthalmic ailments exterior of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA because the proprietary identify for EYP-1901. DURAVYU is an investigational product; it has not been accepted by the FDA. FDA approval and the timeline for potential approval is unsure.
